BioSpace News Archive

Aerie Pharmaceuticals, Inc. announced that the initial purchasers of the previously announced offering of Aerie’s 1.50% Convertible Senior Notes due 2024 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended, have elected to fully exercise their option to purchase an additional $41.25 million aggregate principal amount of the notes.

In a new article published today in The Milbank Quarterly, a multidisciplinary journal of population health and health policy, researchers from Harvard Business School (HBS) and Harvard T.H. Chan School of Public Health, discuss the results of a recently conducted study that assessed the current levels of engagement by businesses in a corporate Culture of Health (CoH).

LC GC®, a leading multimedia platform of peer-reviewed technical information on the field of chromatography and the separation sciences, will host the live webcast, “Advances in Gas Chromatography for DHA, PONA and PIANO Analysis, in Fuels by Single and Multidimensional GC Techniques” on Thursday, Sep. 12, at 11 a.m. EDT, 8 a.m.

Despite health benefits for both mother and baby, many breastfeeding moms stop nursing when they return to work due to their commute, work schedule, unsuitable nursing room conditions, or general lack of awareness or support in the workplace.

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the appointment of Celia Eckert as vice president, general counsel and corporate secretary.

Therap is being used by a growing number of regional centers in California to submit Special Incident Reports (SIR) through its incident management and general event report (GER) module.

Sanford Guide® announces the availability of its industry-leading infectious diseases guidelines through lab reports generated by Wise Diagnostic Systems.

Functional Neuromodulation has initiated the global ADvance II Study, a pivotal clinical trial to assess deep brain stimulation (DBS) in patients with mild Alzheimer’s Disease.

GE Healthcare and Germfree are joining expertise to develop a fully integrated, expandable manufacturing solution for emerging biotherapeutics, including gene therapy.

Allyala Nandakumar and Serge Resnikoff Bring Expertise in Global Health and Vision